Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

Affiliations

¹ University Clinic for Dermatology, Minden, Germany.
² Department of Dermatology, Hospital Universitaria 12 de Cubre, Madrid, Spain.
³ Department of Dermatology, Hôpital Saint-Louis, Paris, France.
⁴ Department of Medical Science, University of Turin Medical School, Turin, Italy.
⁵ Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
⁶ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
⁷ Department of Dermatology, National and Kapodistrian University of Athens, Athens, Greece.
⁸ Department of Dermatology, St. Josef Hospital, UK RUB, Bochum, Germany.
⁹ EORTC Headquarters, Brussels, Belgium.
¹⁰ Department of Dermatology, University Hospital Birmingham, Birmingham, United Kingdom.

Rudolf Stadler et al. Eur J Cancer. 2021 Oct.

. 2021 Oct:156 Suppl 1:S22-S23.

doi: 10.1016/S0959-8049(21)00668-7.

¹ University Clinic for Dermatology, Minden, Germany.
² Department of Dermatology, Hospital Universitaria 12 de Cubre, Madrid, Spain.
³ Department of Dermatology, Hôpital Saint-Louis, Paris, France.
⁴ Department of Medical Science, University of Turin Medical School, Turin, Italy.
⁵ Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
⁶ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
⁷ Department of Dermatology, National and Kapodistrian University of Athens, Athens, Greece.
⁸ Department of Dermatology, St. Josef Hospital, UK RUB, Bochum, Germany.
⁹ EORTC Headquarters, Brussels, Belgium.
¹⁰ Department of Dermatology, University Hospital Birmingham, Birmingham, United Kingdom.

No abstract available

Keywords: Atezolizumab; Sézary syndrome; mycosis fungoides.

LinkOut - more resources